NCT01422304View on ClinicalTrials.gov

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,198

Participants

Timeline

Start Date

October 12, 2011

Primary Completion Date

September 26, 2012

Study Completion Date

September 26, 2012

Conditions
Neuromuscular BlockadeArthroplasty, Replacement, HipArthroplasty, Replacement, KneeBlood CoagulationAntithrombotic Agents
Interventions
DRUG

Sugammadex

Sugammadex 4 mg/kg intravenously

DRUG

neostigmine and glycopyrrolate or atropine

Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels

DRUG

Placebo to neostigmine

Normal saline (NaCl 0.9%)

DRUG

Placebo to sugammadex

Normal saline (NaCl 0.9%)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01422304 - Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) | Biotech Hunter | Biotech Hunter